EP 1086373 A1 20010328 - CD7
Title (en)
CD7
Title (de)
CD7
Title (fr)
CD7
Publication
Application
Priority
- US 9913210 W 19990610
- US 8880098 P 19980610
Abstract (en)
[origin: WO9964857A1] The present invention relates, in general, to CD7 and, in particular, to a method of identifying individuals predisposed to autoimmune diseases based on CD7 analyses. The invention further relates to a method of treating patients suffering from autoimmune diseases by modulating CD7 expression and/or function. The present invention also relates to a method of identifying individuals predisposed to lipopolysaccharide (LPS)-induced shock, as well as to asthma or to other events and sequelae of infections mediated by TNF alpha and gamma-interferon (IFN- gamma ). The invention further relates to a method of treating patients suffering from septic shock, or preventing septic shock in patients predisposed to develop septic shock, by modulating CD7 expression and/or function. In addition, the invention relates to a method of treating patients suffering from asthma or from events and sequelae of infections mediated by TNF alpha or IFN- gamma , or preventing asthma or such events and sequelae of infections mediated by TNF alpha and IFN- gamma in patients predisposed to develop asthma or these events and sequelae, by modulating CD7 expression and/or function. The invention additionally relates to compositions suitable for use in such methods.
IPC 1-7
IPC 8 full level
C12Q 1/68 (2006.01); C12Q 1/6883 (2018.01)
CPC (source: EP)
C12Q 1/6883 (2013.01); C12Q 2600/156 (2013.01); C12Q 2600/158 (2013.01); G01N 2500/10 (2013.01)
Citation (search report)
See references of WO 9964857A1
Designated contracting state (EPC)
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE
DOCDB simple family (publication)
WO 9964857 A1 19991216; AU 4436599 A 19991230; CA 2334491 A1 19991216; EP 1086373 A1 20010328
DOCDB simple family (application)
US 9913210 W 19990610; AU 4436599 A 19990610; CA 2334491 A 19990610; EP 99927469 A 19990610